Filing Flows › ADC Therapeutics SA (ADCT) › Q2 2026 › vs Q2 2025
ADC Therapeutics SA (ADCT) Q2 2026 vs Q2 2025 (year over year)
ADC Therapeutics SA's revenue rose $409K (+2%) from $18.8M in Q2 2025 to $19.2M in Q2 2026. The biggest changes: Product revenues, net +$549K (+3%); Royalties −$140K (-19%).
ADC Therapeutics SA, Q2 2026: revenue $19.2M (+2% year over year), operating margin -132.0%, net loss $16.6M, operating cash flow −$11.8M. The chart draws each line against Q2 2025, the increases inside each band.
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| Product revenues, net | $18.6M | $18.1M | $549K | +3% |
| Royalties | $614K | $754K | −$140K | -19% |
| Revenue | $19.2M | $18.8M | $409K | +2% |
| Other income, net | $8.8M | −$11.2M | $20.1M | — |
| Net loss | $16.6M | $56.6M | −$40.1M | -71% |
| Costs & expenses | $44.7M | $75.5M | −$30.8M | -41% |
| Operating costs | $44.7M | $63.0M | −$18.3M | -29% |
| Research & development | $17.4M | $30.1M | −$12.7M | -42% |
| Sales & marketing | $12.6M | $10.1M | $2.4M | +24% |
| General & admin | $9.7M | $8.8M | $879K | +10% |
| Other operating costs | $5.0M | $13.9M | −$8.9M | -64% |
| Operating cash sources | $16.6M | $56.3M | −$39.7M | -71% |
| Share-based compensation | $4.5M | $1.8M | $2.7M | +151% |
| Working capital & other | $208K | $30.4M | −$30.2M | -99% |
| Cash used in operations | $11.8M | $24.1M | −$12.3M | -51% |
| Net loss absorbed | $16.6M | $56.6M | −$40.1M | -71% |
Questions
How much did ADC Therapeutics SA's revenue grow year over year in Q2 2026?
ADC Therapeutics SA's revenue rose $409K (+2%) from $18.8M in Q2 2025 to $19.2M in Q2 2026.
What drove ADC Therapeutics SA's revenue change in Q2 2026?
Product revenues, net +$549K (+3%); Royalties −$140K (-19%).